Offerings - Offering: 1 |
Aug. 06, 2026
USD ($)
shares
|
|---|---|
| Offering: | |
| Fee Previously Paid | false |
| Other Rule | true |
| Security Type | Equity |
| Security Class Title | Common Stock, $0.01 par value |
| Amount Registered | shares | 4,680,000 |
| Proposed Maximum Offering Price per Unit | 84.18 |
| Maximum Aggregate Offering Price | $ 393,962,400 |
| Fee Rate | 0.01381% |
| Amount of Registration Fee | $ 54,406.21 |
| Offering Note | Reflects new shares of common stock, $0.01 par value per share, of Haemonetics Corporation (the “Common Stock”) registered hereby under the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan (the “Plan”). Pursuant to Rule 416 under the Securities Act of 1933, as amended (the “Securities Act”), this Registration Statement on Form S-8 shall also cover any additional shares of Common Stock that may become issuable under the Plan by reason of any stock dividend, stock split, recapitalization, or any other similar transaction. Estimated solely for the purpose of determining the registration fee pursuant to Rules 457(c) and 457(h) under the Securities Act, based on the average of the high and low prices of the Common Stock as reported on the New York Stock Exchange on July 31, 2026.
|